2Narahara Y, Kanazawa H, Sakamoto C, et al. The efficacy and safetofterli- ressin and albumin in patients with type 1 hepatorenal syndrome:a multi- center, open-label, explorativestudy [ J ]. Gastroenterol, 2012,47 ( 3 ) : 313 -320.
4Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis [J]. Hepatology, 2008, 48(6):2064-2077.
5Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study[J]. Eur J Gastroenterol Hepatol, 2002, 14(2): 153-158.
6Runyon BA. Management of adult patients with ascites due to cirrhosis: an update[J]. Hepatology, 2009, 49(6):2087-2107.
7Ortega R, Gin,s P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study[J]. Hepatology, 2002, 36(4 Pt 1): 941-948.
8Triantos CK, Samonakis D, Thalheimer U, et al. Terlipressin therapy for renal failure in cirrhosis[J]. Eur J Gastroenterol Hepatol, 2010, 22(4):481-486.
9Ichai C, Passeron C, Caries M, et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: a single-blind, prospective, controlled study[J]. Crit Care Med, 2000, 28(5):1329-1335.
10Ichai C, Soubielle J, Caries M, et al. Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: a single-blind randomized study[J]. Crit Care Med, 2000, 28(4):921-928.
